Treatment and 1-Year Prognosis of Ischemic Stroke in China in 2018: A Hospital-Based Study from Bigdata Observatory Platform for Stroke of China
Wen-Jun Tu,Feng Yan,Bao-Hua Chao,Lei Cao,Longde Wang
DOI: https://doi.org/10.1161/strokeaha.121.038260
IF: 10.17
2022-01-01
Stroke
Abstract:HomeStrokeVol. 53, No. 9Treatment and 1-Year Prognosis of Ischemic Stroke in China in 2018: A Hospital-Based Study From Bigdata Observatory Platform for Stroke of China Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessResearch ArticlePDF/EPUBTreatment and 1-Year Prognosis of Ischemic Stroke in China in 2018: A Hospital-Based Study From Bigdata Observatory Platform for Stroke of China Wen-Jun Tu, Feng Yan, Bao-Hua Chao, Lei Cao and Longde Wang Wen-Jun TuWen-Jun Tu https://orcid.org/0000-0002-1703-1802 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (W.-J.T.). The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). , Feng YanFeng Yan The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). , Bao-Hua ChaoBao-Hua Chao The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). , Lei CaoLei Cao The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). and Longde WangLongde Wang Correspondence to: Longde Wang, MD, No. 118, Guang'anmen Inner St, Beijing, 100053, China. Email E-mail Address: [email protected] https://orcid.org/0000-0002-2156-7909 The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, Beijing, China (W.-J.T., F.Y., B.-H.C., L.C., L.W.). Originally published22 Jul 2022https://doi.org/10.1161/STROKEAHA.121.038260Stroke. 2022;53:e415–e417Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: July 22, 2022: Ahead of Print Stroke is associated with the highest disability-adjusted life years lost in China, with over 2 million new cases annually.1 In addition, deaths caused by stroke are rising rapidly in China, more so than in other countries.2 However, there are few studies that have provided nationwide data on stroke treatment and outcomes in China. This study aims to assess the treatment and 1-year prognosis of ischemic stroke in China in 2018.MethodsIn December 2017, we randomly selected 100 hospitals (at least one in each province) from the Bigdata Observatory Platform for Stroke of China3 (Supplemental Material I). Hospitals participating in the Bigdata Observatory Platform for Stroke of China included mandatory and voluntary. From January to December 2018, all patients with first-ever ischemic stroke and symptom onset within 14 days were included. The Ethics Committee of Brain Hospital of Hunan Province (No. Z2017006) and Peking Union Medical College Hospital (JS-2289) approved this study, and written informed consent was obtained. A complete description of the information collected has been reported previously.3 Telephone follow-up was conducted after 1 year after baseline. Case fatality, disability, and recurrence rates were assessed, and a percentage and 95% CIs were presented. Multivariable logistic regression was used to examine the association of variables with the odds of outcomes (Supplemental Material II).ResultsIn total, 74 904 ischemic strokes from 83 hospitals from 30 provinces (median [interquartile range] age, 68 [58–74] years; 61.27% male) were recruited. Two thousand six hundred eighty-nine (3.59% [95% CI, 3.46%–3.72%]) patients received thrombolytic therapy and 820 (1.09%) patients received thrombectomy treatment. At discharge, the fatality rate was 1.23% (95% CI, 1.15%–1.31%). The discharge against medical advice rate was 5.34% (95% CI, 5.18%–5.50%; Table S1). In-hospital fatality rate was higher in those old patients (≥60 years) than in those young patients (<60 years). There were regional differences in the in-hospital fatality rate (Figure).Download figureDownload PowerPointFigure. Subgroup analysis in the discharge and 1-y follow-up (those results were unweighted data as % [95% CI]). Disability was defined as an modified Rankin Scale (mRS) of 3 to 5 points. bModel covariates were age, sex, history of stroke, hypertension, diabetes, hyperlipidemia, atrial fibrillation, coronary artery disease, coagulopathy, heart failure, peripheral arterial disease, carotid stenosis, hyperhomocysteinemia, stroke severity, hospital grade, region, stroke unit, and teaching hospital status. Sex: female vs male; age: ≥60 vs <60. cThe highest-level region vs lowest region; in-hospital fatality: Northwest China (NW) vs CC, in-hospital fatality/discharge against medical advice (DAMA): SW vs NC; 1-year fatality: SC vs North China (NC), 1-year recurrence: Northeast China (NE) vs SC, 1-year disability: SC vs NC. d,e,fRepresent the P for each region compared with North China (NC), which we have selected as the reference region; dFor P<0.05, efor P<0.01, and ffor P<0.001. CC indicates Central China; EC, East China; N, number of patients; n, number of hospitals; and SW, Southwest China.During the follow-up period, the fatality rate was 6.81% (95% CI, 6.62%–7.00%; Table S2. The fatality rate was higher in those old patients than in those young patients. In addition, men patients had a lower fatality rate than women. The fatality rate varied significantly between different regions (Figure). The case recurrence rate was 7.74% (95% CI, 7.54%–7.94%), and the disability rate of stroke survivors was 15.42% (95% CI, 15.14%–15.70%; Table S2). Stroke recurrence rate and disability rate of stroke survivors were higher in those old patients than in those young patients and varied greatly between different regions (Figure).DiscussionThis nationwide study shows the rate of thrombolytic therapy and 1-year outcomes in patients with ischemic stroke. Another study showed that the in-hospital death/discharge against the medical advice rate was 5.3% (5.0%–5.5%) for ischemic stroke.4 The China Kadoorie Biobank showed that among those who survived 28 days after the first stroke, the 1-year case fatality and recurrence rates were 4% and 17%.5 The prognosis of ischemic stroke in China is better than in high-income countries despite the low thrombolytic rates.1 Furthermore, the fatality and disability rates trend are low in north China and high in the south, while the recurrence rate shows the opposite direction. Hospitals with a low sample size and low follow-up rate were excluded. This may cause selection bias as patients in these excluded hospitals might have less access to treatment and worse outcomes. This study provides a scientific basis for the Chinese population by establishing a database of stroke patients in China, studying the rules and trends of disease treatment and prognosis.Article InformationSources of FundingThis study was supported by the National Major Public Health Service Projects.Supplemental MaterialBigdata Observatory Platform for Stroke of ChinaSupplemental Materials and MethodsTables S1–S2FootnotesSupplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.121.038260.Correspondence to: Longde Wang, MD, No. 118, Guang'anmen Inner St, Beijing, 100053, China. Email wangld@nhfpc.gov.cnReferences1. Wu S, Wu B, Liu M, Chen Z, Wang W, Anderson CS, Sandercock P, Wang Y, Huang Y, Cui L, et al; China Stroke Study Collaboration. Stroke in China: advances and challenges in epidemiology, prevention, and management.Lancet Neurol. 2019; 18:394–405. doi: 10.1016/S1474-4422(18)30500-3CrossrefMedlineGoogle Scholar2. Li Z, Jiang Y, Li H, Xian Y, Wang Y. China's response to the rising stroke burden.BMJ. 2019; 364:l879. doi: 10.1136/bmj.l879CrossrefMedlineGoogle Scholar3. Shen Y, Chao BH, Cao L, Tu WJ, Wang LD. Stroke center care and outcome: results from the CSPPC stroke program.Transl Stroke Res. 2020; 11:377–386. doi: 10.1007/s12975-019-00727-6CrossrefGoogle Scholar4. Tu WJ, Chao BH, Ma L, Yan F, Cao L, Qiu H, Ji XM, Wang LD. Case-fatality, disability and recurrence rates after first-ever stroke: a study from bigdata observatory platform for stroke of China.Brain Res Bull. 2021; 175:130–135. doi: 10.1016/j.brainresbull.2021.07.020CrossrefGoogle Scholar5. Chen Y, Wright N, Guo Y, Turnbull I, Kartsonaki C, Yang L, Bian Z, Pei P, Pan D, Zhang Y, et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0· 5 million Chinese adults.Lancet Glob Health. 2020; 8:e580–e590. doi: 10.1016/S2214-109X(20)30069-3CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Tu W and Xu Y (2023) A response to a letter to the editor TR-D-22-00887, Thrombosis Research, 10.1016/j.thromres.2023.01.009, 223, (34-35), Online publication date: 1-Mar-2023. Tu W, Xu Y, Chen H, Li J and Du J (2023) Impact of the COVID-19 pandemic lockdown on hospitalizations for cerebrovascular disease and related in-hospital mortality in China: A nationwide observational study, Archives of Gerontology and Geriatrics, 10.1016/j.archger.2022.104832, 104, (104832), Online publication date: 1-Jan-2023. Tu W, Xu Y, Liu Y, Du J and Zhao J (2022) Endovascular thrombectomy or bridging therapy in minor ischemic stroke with large vessel occlusion, Thrombosis Research, 10.1016/j.thromres.2022.09.020, 219, (150-154), Online publication date: 1-Nov-2022. September 2022Vol 53, Issue 9 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.121.038260PMID: 35866427 Originally publishedJuly 22, 2022 Keywordsischemic strokeprognosisdisability-adjusted life yearshospitaltreatment outcomePDF download Advertisement SubjectsIschemic Stroke